Rezdiffra (Resmetirom) Cost in Alaska 2026: Pricing, Insurance, and Savings Options

What Does Rezdiffra (Resmetirom) Cost in Alaska Right Now?

The manufacturer list price set by Madrigal Pharmaceuticals for Rezdiffra is $3,500 per month, and Alaska retail pharmacies reflect that same figure for cash-pay customers in 2026. This price applies to both the 60 mg and 100 mg tablet strengths, taken once daily.

Alaska's pharmacy market presents unique cost pressures. The state has fewer retail pharmacy locations per capita than most of the lower 48, and supply chain logistics (particularly for specialty drugs shipped to remote communities) can add handling fees. For Rezdiffra specifically, the FDA-approved labeling establishes weight-based dosing: patients under 100 kg take 80 mg daily (one 60 mg tablet plus one 20 mg tablet reconstituted from the packaging), while patients at or above 100 kg take 100 mg daily. Both dose levels carry the same monthly cost at retail.

At $42,000 per year, Rezdiffra ranks among the more expensive hepatology drugs, though it falls below the annual cost of several biologic therapies used in liver disease. For context, obeticholic acid (Ocaliva) carried a list price exceeding $69,000 annually before its indication was withdrawn by the FDA due to lack of confirmed clinical benefit. Rezdiffra is now the only FDA-approved pharmacotherapy specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis stages F2 or F3 [1].

Patients paying cash should ask their pharmacy about any available prompt-pay discounts. Some Alaska-based independent pharmacies and regional chains offer modest reductions for upfront payment. These discounts are not standardized and typically range from 2% to 5%.

Alaska Medicaid and Rezdiffra: Current Coverage Status

Alaska Medicaid does not cover Rezdiffra as of 2026. This means beneficiaries enrolled in standard Medicaid, Denali KidCare, or any Medicaid managed care arrangement in Alaska cannot obtain Rezdiffra through their state benefit.

The absence of coverage is not unique to Alaska. Many state Medicaid programs have been slow to add Rezdiffra to their preferred drug lists, partly because the drug received accelerated approval from the FDA in March 2024 based on a surrogate endpoint (reduction in liver fat on biopsy at 52 weeks) rather than a confirmed clinical outcome like reduced cirrhosis progression or mortality. Medicaid pharmacy committees frequently wait for full approval or long-term outcomes data before adding specialty drugs to formularies.

The MAESTRO-NASH trial (N=966) demonstrated that resmetirom 80 mg achieved MASH resolution without worsening fibrosis in 25.9% of patients versus 9.7% for placebo at 52 weeks, and the 100 mg dose achieved this in 29.9% of patients [1]. A fibrosis improvement endpoint (one or more stage reduction with no worsening of NASH Activity Score) was met by 24.2% on the 80 mg dose and 25.9% on the 100 mg dose, compared with 14.2% on placebo [1]. These histological results, published in the New England Journal of Medicine, formed the basis of the accelerated approval.

Alaska Medicaid beneficiaries seeking coverage may file a prior authorization exception request. The Alaska Department of Health has a process for non-formulary drug exceptions when a prescriber documents medical necessity and prior treatment failure. Success rates for these requests with newly approved specialty drugs are low, but not zero. Physicians should include biopsy-confirmed fibrosis staging, evidence of failed lifestyle intervention, and relevant comorbidities (type 2 diabetes, obesity, dyslipidemia) in the prior authorization submission.

Commercial Insurance Coverage for Rezdiffra in Alaska

Coverage through employer-sponsored and individual commercial plans in Alaska varies widely. The three largest insurers operating in the state (Premera Blue Cross Blue Shield of Alaska, Moda Health, and Aetna) each maintain independent pharmacy and therapeutics committees that evaluate new specialty drugs on different timelines.

As of early 2026, some commercial plans have added Rezdiffra with step therapy requirements. A typical step therapy protocol requires documentation of at least 6 months of structured lifestyle modification (diet and exercise), a confirmed MASH diagnosis via liver biopsy or validated noninvasive testing, and fibrosis staging of F2 or F3. Plans generally exclude patients with decompensated cirrhosis (Child-Pugh B or C), as the MAESTRO-NASH trial excluded this population.

Patients should take these steps to determine their coverage:

1. Call the member services number on the back of the insurance card and ask specifically whether resmetirom (brand name Rezdiffra, NDC numbers associated with the Madrigal product) is on formulary.
2. Request the prior authorization criteria in writing.
3. Ask whether the drug is classified as a pharmacy benefit or a medical benefit, as this affects copay structures and out-of-pocket maximum calculations.
4. Confirm whether a specialty pharmacy is required. Many plans mandate use of a preferred specialty pharmacy network, which in Alaska may mean mail-order delivery rather than local pickup.

Copay obligations under commercial plans that do cover Rezdiffra range from $50 to $500 per month depending on the plan's specialty tier structure. High-deductible health plans common among Alaska's small employers may require full cost until the deductible is met.

According to the Endocrine Society's 2023 clinical practice guideline on NAFLD/MASH management, pharmacotherapy should be considered for patients with biopsy-proven NASH and fibrosis stage F2 or higher. Including this guideline citation in prior authorization letters strengthens the medical necessity argument.

Compounded Resmetirom in Alaska: Legality and Availability

Compounded resmetirom is available in Alaska through 503A compounding pharmacies. This is legal under federal law (section 503A of the Federal Food, Drug, and Cosmetic Act) and Alaska state pharmacy regulations.

A 503A pharmacy compounds medications on a patient-specific basis with a valid prescription. The compounded product is not FDA-approved and is not bioequivalent-tested against the branded Rezdiffra tablet. Patients considering this route should understand several practical realities.

First, cost. Compounded resmetirom pricing from 503A pharmacies has been reported at dramatically lower price points than the branded product, in some cases near the cost of raw materials plus compounding fees. However, pricing varies substantially between pharmacies and may change as demand and raw material costs shift.

Second, quality. The FDA has raised general concerns about compounded drugs not undergoing the same rigorous manufacturing controls as commercially approved products. Potency, purity, and stability testing standards differ between 503A pharmacies and FDA-inspected manufacturing facilities. The Alaska Board of Pharmacy oversees 503A facilities operating within the state, but inspection frequency and depth vary.

Third, insurance. Compounded medications are almost never covered by insurance. Patients choosing this route will pay out of pocket entirely.

Fourth, prescriber willingness. Some hepatologists and gastroenterologists are reluctant to prescribe compounded versions of newly approved drugs, citing liability concerns and uncertainty about bioavailability. Others view it as a reasonable option for patients who cannot afford the branded product and would otherwise go untreated.

Alaska has a small number of 503A compounding pharmacies, concentrated in Anchorage, Fairbanks, and Juneau. Patients in rural areas may need to work with a compounding pharmacy that ships within the state. The prescribing physician must write a patient-specific prescription; 503A pharmacies cannot compound resmetirom "in anticipation of" prescriptions for general stock.

Madrigal Pharmaceuticals Savings Card and Patient Assistance

Madrigal Pharmaceuticals offers a copay savings card for commercially insured patients. The card reduces out-of-pocket costs for eligible patients, typically capping copays at $0 to $50 per month depending on the specific program terms in effect.

Eligibility requirements include having commercial insurance that covers Rezdiffra (the card does not substitute for insurance coverage), not being enrolled in any government-funded healthcare program (Medicare, Medicaid, TRICARE, VA), and filling the prescription at a participating pharmacy.

For uninsured or underinsured patients, Madrigal operates a separate patient assistance program (PAP) that may provide Rezdiffra at no cost. Income thresholds for PAP eligibility are typically set at or below 400% of the federal poverty level, though Madrigal's specific criteria should be confirmed directly through their patient support line or website.

Alaska patients should note that manufacturer copay cards do not count toward the out-of-pocket maximum under most commercial plans due to copay accumulator programs. Several major insurers in Alaska have implemented accumulator adjustment policies. This means the savings card payment may not reduce the patient's remaining deductible or out-of-pocket obligation. Patients should ask their insurer directly whether copay card payments count toward accumulators.

The American Association for the Study of Liver Diseases (AASLD) practice guidance on NAFLD/MASH emphasizes that treatment access barriers, including drug cost, contribute to disease progression in a condition affecting an estimated 6 to 8 million Americans with at-risk NASH [2]. Alaska's MASH prevalence data is limited, but the state's rates of obesity (34.2% of adults per CDC BRFSS data) and type 2 diabetes suggest a substantial affected population.

Telehealth Prescribing of Rezdiffra in Alaska

Telehealth prescribing of Rezdiffra is permitted in Alaska. The state's telehealth parity laws allow licensed physicians to evaluate patients and prescribe medications, including specialty drugs, via video or audio visits. This is relevant for Alaska in particular because geographic barriers make in-person specialist visits impractical for many residents.

A hepatologist or gastroenterologist licensed in Alaska (or holding an appropriate interstate medical license) can prescribe Rezdiffra after a telehealth evaluation. The clinical evaluation should include review of liver biopsy results or validated noninvasive fibrosis markers (FibroScan, FIB-4 index, ELF test), metabolic comorbidity assessment, and baseline laboratory work (hepatic function panel, lipid panel, thyroid function).

Resmetirom is a thyroid hormone receptor beta (THR-beta) selective agonist. The MAESTRO-NASH safety data showed that the most common adverse effects were diarrhea (27% on 80 mg, 33% on 100 mg vs. 15% placebo) and nausea (13% on 80 mg, 19% on 100 mg vs. 8% placebo) [1]. Thyroid function monitoring is recommended, as the drug can reduce TSH and total T4 levels, though clinical hypothyroidism events were rare in the trial. These monitoring requirements are manageable via telehealth with local lab draws.

Patients in rural Alaska communities (Bethel, Nome, Kotzebue, Barrow/Utqiagvik, Dillingham) can access Rezdiffra prescriptions through telehealth and receive the medication via mail-order specialty pharmacy. The Alaska Tribal Health System, which serves Alaska Native and American Indian beneficiaries through facilities like the Alaska Native Medical Center, may also provide access pathways, though formulary coverage through tribal health programs should be confirmed individually.

How Rezdiffra Compares to Lifestyle Intervention Alone

The decision to start Rezdiffra at $3,500 per month raises a fair question: how does the drug's benefit compare to intensive lifestyle modification, which costs far less?

The evidence is clear that weight loss of 7% to 10% of body weight can produce MASH resolution and fibrosis improvement. A 2019 prospective study published in Gastroenterology (N=293) showed that 10% or greater weight loss achieved NASH resolution in 90% of patients and fibrosis improvement in 45% [3]. The problem is adherence. Only 10% of participants in that study actually achieved 10% weight loss over 52 weeks.

Rezdiffra's MASH resolution rate of 25.9% to 29.9% at 52 weeks [1] is lower than what aggressive weight loss can achieve, but it is achievable by simply taking a daily pill. The two approaches are not mutually exclusive. The MAESTRO-NASH protocol included standard-of-care lifestyle counseling for all participants, including those on active drug.

For Alaska patients weighing the $42,000 annual cost, the calculus depends on fibrosis stage, rate of progression, comorbidity burden, and realistic assessment of whether sustained weight loss is achievable. GLP-1 receptor agonists (semaglutide, tirzepatide) represent another pharmacotherapy avenue that produces weight loss and has shown liver-related benefits in clinical trials, though neither is FDA-approved specifically for MASH. The STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks [4], and a phase 2 trial of semaglutide in NASH showed dose-dependent NASH resolution [5].

"For patients with biopsy-confirmed MASH and significant fibrosis who have not responded to lifestyle changes, resmetirom offers the first approved pharmacologic option," stated the Endocrine Society clinical practice guideline on metabolic liver disease. A second expert perspective from the AASLD notes: "Access to approved NASH therapies must be addressed as a health equity priority, particularly in states with geographic barriers to specialist care" [2].

Practical Steps to Reduce Rezdiffra Costs in Alaska

Patients and prescribers in Alaska can take a structured approach to minimize Rezdiffra costs:

Step 1: Verify insurance coverage. Contact the insurer before filling the prescription. Obtain the prior authorization form and have the prescribing physician complete it with biopsy or imaging results, fibrosis stage, and documentation of lifestyle intervention.

Step 2: Apply for the Madrigal copay savings card. If commercially insured and the drug is covered, the savings card can reduce monthly copays substantially. Apply through the manufacturer's patient support program.

Step 3: Explore patient assistance. If uninsured or if insurance denies coverage, apply to Madrigal's patient assistance program. Income documentation will be required.

Step 4: Consider compounding. If cost remains prohibitive and the prescriber is willing, a 503A compounding pharmacy in Alaska can prepare resmetirom at a lower price point. Discuss quality assurance and monitoring with the prescriber.

Step 5: Appeal denials. If insurance denies coverage, file a formal appeal. Include peer-reviewed citations (MAESTRO-NASH, AASLD guidance, Endocrine Society guideline), the patient's specific fibrosis stage, and a letter of medical necessity. Alaska's Division of Insurance allows external review of denied claims.

Step 6: Check tribal health eligibility. Alaska Native and American Indian patients should contact their tribal health organization to ask about specialty drug access programs that may cover or offset Rezdiffra costs.

The most cost-effective path for most Alaska patients with commercial insurance will be: obtain prior authorization, apply the manufacturer copay card, and confirm whether the copay card payment counts toward the plan's accumulator. For uninsured patients, the patient assistance program or compounding route offers the most realistic access. Monitoring on resmetirom should include hepatic function every 3 months for the first year and thyroid function at baseline and 4 to 8 weeks after initiation, per the FDA prescribing information.